Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-CVac for Malaria Protection
NCT02115516Phase 1Completed
- Sponsor
- Sanaria Inc.
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ Challenge in Plasmodium falciparum malaria (8 arms), sponsored by Sanaria Inc. Primary endpoints: Proportion of volunteers who become parasitemic and Occurrence of related Grade 3 adverse events and SAEs at 19 months. Started Apr 2014; status: completed.
02
Drugs
PfSPZ Challenge
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT02115516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115516.